Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
04/27/2012
Trade Name:
Lexiva
Generic Name or Proper Name (*):
fosamprenavir
Indications Studied:
Treatment of HIV-1 infection
Label Changes Summary:
Expanded indication to include pediatric patients at least 4 weeks - <2 years; previously approved for use in 2 18 years The PK, safety, tolerability, and efficacy in pediatric patients < 4 weeks have not been established Dosing of Lexiva plus ritonavir is not recommended for protease inhibitor-experienced pediatric patients <6 months of age; data do not support twice-daily dosing of Lexiva without ritonavir in pediatric patients <2 years Weight-adjusted apparent clearance was higher in children < 4 years, suggesting that younger children require higher mg per kg dosing of Lexiva Vomiting and neutropenia were more frequent in pediatrics than in adults. Other adverse reactions were similar to adults Information on dosing, clinical trials, PK and adverse reactions New dosage regimen for patients at least 4 weeks - < 6 years; Postmarketing study
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B, P
Sponsor:
ViiV Healthcare
Pediatric Exclusivity Granted Date:
01/10/2012
NNPS:
FALSE'
Therapeutic Category:
Antiviral
-
-